tumor mutational burden
Epic Sciences Raises $24M, Expands Commercial Infrastructure for Breast Cancer Liquid Biopsy Test
The firm is growing its sales, product marketing, and customer service teams for its multiomic metastatic breast cancer liquid biopsy test, DefineMBC.
In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
Illumina Obtains CE-IVD Marking for European Version of TSO Comprehensive Assay
The next-generation sequencing-based assay detects variants in 517 genes and genomic signatures using formalin-fixed, paraffin-embedded tumor tissue samples.
Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.